id,patient_id,referenceGenome,hugoSymbol,entrezGeneId,alteration,alterationType,svType,tumorType,consequence,proteinStart,proteinEnd,hgvs,geneExist,variantExist,alleleExist,oncogenic,mutationEffectDescription,knownEffect,citationPMids,citationAbstracts,highestSensitiveLevel,highestResistanceLevel,highestDiagnosticImplicationLevel,highestPrognosticImplicationLevel,highestFdaLevel,otherSignificantSensitiveLevels,otherSignificantResistanceLevels,hotspot,geneSummary,variantSummary,tumorTypeSummary,prognosticSummary,diagnosticSummary,diagnosticImplications,prognosticImplications,treatments,dataVersion,lastUpdate,vus,sample_id
16,33,,MET,4233,Amplification,,,HGSOC,,,,,,,,Oncogenic,"MET amplification results from the gain of the MET gene on chromosome 7 (PMID: 17463250).",Gain-of-function,"30073261,16461907,19117057,17667909,22869872,18077425,18093943,28481359,17463250",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"MET, a receptor tyrosine kinase.",,,[],[],Crizotinib;Telisotuzumab Vedotin;Capmatinib;Tepotinib,v3.14,2023-02-26,,91
17,34,,MET2,4234,Amplification,,,HGSOC,,,,,,,,Oncogenic,"MET amplification results from the gain of the MET gene on chromosome 7 (PMID: 17463250).",Gain-of-function,"30073261,16461907",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"MET, a receptor tyrosine kinase.",,,[],[],Crizotinib;Telisotuzumab Vedotin;Capmatinib,v3.14,2023-02-26,,92
